With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight.
But with oncology now taking up the vast bulk of its R&D expenditure, it’s worth taking a closer look at a company which is also on the prowl for partnerships and acquisitions in this area.
The French pharmaceutical and beauty care company has significantly advanced its oncology portfolio through several strategic initiatives and collaborations in 2023 and 2024.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze